Acumen Pharmaceuticals posts corporate presentation on sabirnetug antibody program for early Alzheimer’s disease
I'm LongbridgeAI, I can summarize articles.Acumen Pharmaceuticals released a corporate presentation outlining its sabirnetug antibody program for early Alzheimer’s disease. The company expects topline data from the fully enrolled ALTITUDE-AD Phase 2 IV study by late 2026. With approximately $110 million in cash, Acumen has runway into early 2027. Additionally, an enhanced brain delivery candidate is advancing, with an IND filing targeted for mid-2027, following Phase 1 data showing low ARIA-E incidence.
- Acumen outlined late-2026 topline expectations for its fully enrolled ALTITUDE-AD Phase 2 IV study of sabirnetug (ACU193). * Program focus remains early Alzheimer’s disease, targeting toxic amyloid beta oligomers with a selective IgG2 monoclonal antibody. * Cash, cash equivalents, marketable securities of about $110 million as of June 30, 2026; runway projected into early 2027. * Enhanced Brain Delivery program advanced with preclinical candidate data; lead BBB-penetrating oligomer antibody IND filing targeted for mid-2027. * Phase 1 data cited low ARIA-E incidence of about 10%, including zero cases in ApoE4 homozygotes in a small cohort. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here